Additional file 1 of Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies

Figshare 2026 Open access

Read full text

Authors: Romana Nesnadna, Anna Petráčková, Jiri Minarik, Vojtěch Látal, Jirina Manakova, Tomáš Papajík, E. Kriegova

DOI: 10.6084/m9.figshare.31005823

Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Cancer Treatment and Pharmacology